Max G. Bachem
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Max G. Bachem has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Alexandra Schmid-Kotsas
Departments of Clinical Chemistry and Pathobiochemistry, University of Ulm, Ulm, Germany
3 shared publicationsAdolf Grünert
Department of Clinical Chemistry and Pathobiochemistry, University Hospital Ulm, Ulm, Germany
2 shared publicationsGuido Adler
Department of Internal Medicine-Gastroenterology, University of Ulm, Ulm, Germany
2 shared publicationsHans Beger
Department of Surgery, University of Ulm, Ulm, Germany
2 shared publicationsMarco Siech
Department of Surgery, University of Ulm, Ulm, Germany
2 shared publicationsAdolf Gruenert
1 shared publication
Latest Publications
- Top Cited Papers
- 1 April 2005
- Published by Elsevier in Gastroenterology
- Vol. 128 (4) , 907-921
Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells
- 1 April 2005
- Published by Elsevier in Gastroenterology
- Vol. 128 (4) , 907-921
Top Cited PapersPancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells
- 26 January 2002
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 40 (8)
Evaluation of Two Modified Cardiac Troponin I Enzyme Immunoassays
One of the major challenges for manufacturers of troponin immunoassays is to optimize the low-end of the assays because diagnostic and therapeutic interventions are based on decreasing cutpoints. Recently published consensus documents of the European Society of Cardiology and the American College of Cardiology recommended the 99th percentile of a reference control group as cut-off for increased troponin I levels and suggested that imprecision at the 99th percentile for each assay should be < or = 10%. In this study, we have evaluated two newly modified cardiac troponin I (cTnI) enzyme immunoassays (Dimension cTnI assay, Dade Behring, Germany and AIA-PACK cTnI 2nd-Gen, Eurogenetics Tosoh, Belgium). With both assays all measured cTnI values in plasma and serum samples of apparently healthy volunteers were within the reference ranges given by the manufacturers. Intra-assay coefficients of variation of cTnI concentrations above the 99th percentile (given by the manufacturers) were below 17% and decreased with increasing cTnI concentrations. In most samples, the AIA-PACK cTnI assay yielded higher results; however, a close correlation between both assays was observed. Both tests exhibit acceptable overall performance, but (especially the Dimension cTnI assay) do not yet meet the above-mentioned precision in the low-end assay range. These data emphasize the need for cTnI assay standardization and for further optimization at clinical decision levels.
- 26 January 2002
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 40 (8)
Evaluation of Two Modified Cardiac Troponin I Enzyme Immunoassays
One of the major challenges for manufacturers of troponin immunoassays is to optimize the low-end of the assays because diagnostic and therapeutic interventions are based on decreasing cutpoints. Recently published consensus documents of the European Society of Cardiology and the American College of Cardiology recommended the 99th percentile of a reference control group as cut-off for increased troponin I levels and suggested that imprecision at the 99th percentile for each assay should be < or = 10%. In this study, we have evaluated two newly modified cardiac troponin I (cTnI) enzyme immunoassays (Dimension cTnI assay, Dade Behring, Germany and AIA-PACK cTnI 2nd-Gen, Eurogenetics Tosoh, Belgium). With both assays all measured cTnI values in plasma and serum samples of apparently healthy volunteers were within the reference ranges given by the manufacturers. Intra-assay coefficients of variation of cTnI concentrations above the 99th percentile (given by the manufacturers) were below 17% and decreased with increasing cTnI concentrations. In most samples, the AIA-PACK cTnI assay yielded higher results; however, a close correlation between both assays was observed. Both tests exhibit acceptable overall performance, but (especially the Dimension cTnI assay) do not yet meet the above-mentioned precision in the low-end assay range. These data emphasize the need for cTnI assay standardization and for further optimization at clinical decision levels.
- 1 January 2000
- Published by Elsevier in Laboratory Investigation
- Vol. 80 (1) , 47-55
Platelet-Derived Growth Factors Stimulate Proliferation and Extracellular Matrix Synthesis of Pancreatic Stellate Cells: Implications in Pathogenesis of Pancreas Fibrosis
- 1 January 2000
- Published by Elsevier in Laboratory Investigation
- Vol. 80 (1) , 47-55
Platelet-Derived Growth Factors Stimulate Proliferation and Extracellular Matrix Synthesis of Pancreatic Stellate Cells: Implications in Pathogenesis of Pancreas Fibrosis
- 1 March 1999
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 37 (3) , 319-326
Depending on Their Concentration Oxidized Low Density Lipoproteins Stimulate Extracellular Matrix Synthesis or Induce Apoptosis in Human Coronary Artery Smooth Muscle Cells
Various lines of evidence indicate that oxidative stress resulting in lipid peroxidation and protein modification is involved in the pathogenesis of atherosclerosis and coronary heart disease. We have investigated the effect of modified (oxidized) low-density lipoproteins (oxLDL) on collagen and fibronectin synthesis in cultured human coronary artery smooth muscle cells (HCA-SMC). As shown by immunofluorescence microscopy and time-resolved fluorescence immunoassay, oxLDL dose-dependently stimulated collagen type I and fibronectin synthesis in cultured HCA-SMC. The effect on matrix synthesis was biphasic, with a maximum effect at concentrations between 1 and 10 μg/ml oxLDL. Higher oxLDL concentrations (>25 μg/ml) were cytotoxic. Beside oxLDL, malondialdehyde-modified LDL also stimulated extracellular matrix synthesis. In the presence of 100 μg/ml ascorbic acid, 25, 50 and 100 μg/ml oxLDL induced apoptosis within 6–8 hours (demonstrated by TUNEL-reaction, annexin-V binding and APO-2.7-expression). Apoptosis was not induced by normal (unmodified) LDL and malondialdehyde-modified LDL. The radical scavengers and antioxidants TROLOX and probucol and the hydrogen peroxide eliminator catalase significantly reduced oxLDL-induced apoptosis. Our results demonstrate that low concentrations of oxLDL are profibrogenic by stimulating extracellular matrix synthesis, whereas higher oxLDL concentrations induce oxidative stress and apoptosis in coronary artery smooth muscle cells. The profibrogenic effect might be relevant in the formation of atherosclerotic plaques, and the proapoptotic effect might contribute to an increased plaque vulnerability.
- 1 March 1999
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 37 (3) , 319-326
Depending on Their Concentration Oxidized Low Density Lipoproteins Stimulate Extracellular Matrix Synthesis or Induce Apoptosis in Human Coronary Artery Smooth Muscle Cells
Various lines of evidence indicate that oxidative stress resulting in lipid peroxidation and protein modification is involved in the pathogenesis of atherosclerosis and coronary heart disease. We have investigated the effect of modified (oxidized) low-density lipoproteins (oxLDL) on collagen and fibronectin synthesis in cultured human coronary artery smooth muscle cells (HCA-SMC). As shown by immunofluorescence microscopy and time-resolved fluorescence immunoassay, oxLDL dose-dependently stimulated collagen type I and fibronectin synthesis in cultured HCA-SMC. The effect on matrix synthesis was biphasic, with a maximum effect at concentrations between 1 and 10 μg/ml oxLDL. Higher oxLDL concentrations (>25 μg/ml) were cytotoxic. Beside oxLDL, malondialdehyde-modified LDL also stimulated extracellular matrix synthesis. In the presence of 100 μg/ml ascorbic acid, 25, 50 and 100 μg/ml oxLDL induced apoptosis within 6–8 hours (demonstrated by TUNEL-reaction, annexin-V binding and APO-2.7-expression). Apoptosis was not induced by normal (unmodified) LDL and malondialdehyde-modified LDL. The radical scavengers and antioxidants TROLOX and probucol and the hydrogen peroxide eliminator catalase significantly reduced oxLDL-induced apoptosis. Our results demonstrate that low concentrations of oxLDL are profibrogenic by stimulating extracellular matrix synthesis, whereas higher oxLDL concentrations induce oxidative stress and apoptosis in coronary artery smooth muscle cells. The profibrogenic effect might be relevant in the formation of atherosclerotic plaques, and the proapoptotic effect might contribute to an increased plaque vulnerability.